PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10925305-1	2000	Anaphylatoxin derived from the fifth complement component (C5a) in the presence of IL-3 induces continuous leukotriene C4 generation and IL-4 and IL-13 expression in human basophils for a period of 16-18 h. This indicates that the G protein-coupled C5a receptor (C5aR) can induce long-lasting cellular responses.	Leukotrienes	107-118	complement C5a receptor 1	Homo sapiens	59-62	
9933081-1	1999	Basophils stimulated with IL-3 plus C5a selectively express IL-4 and IL-13 and continuously produce leukotrienes (LT) for hours.	Leukotrienes	100-112	complement C5a receptor 1	Homo sapiens	36-39	
8245471-2	1993	IL-3 can cause a qualitative change in the mediator release pattern for C5a-mediated stimulation; without IL-3, C5a causes no leukotriene release whereas in the presence of IL-3, significant leukotriene occurs.	Leukotrienes	126-137	complement C5a receptor 1	Homo sapiens	72-75	
9162173-5	1997	Leukotrienes metabolism is deeply involved in aspirin intolerance or so-called pseudo allergy and, in spite of that the exact mechanism involved is still unknown, leukotriene release in vitro by ASA in the presence C5a represent the first reliable test for this diagnosis.	Leukotrienes	0-12	complement C5a receptor 1	Homo sapiens	215-218	
9162173-5	1997	Leukotrienes metabolism is deeply involved in aspirin intolerance or so-called pseudo allergy and, in spite of that the exact mechanism involved is still unknown, leukotriene release in vitro by ASA in the presence C5a represent the first reliable test for this diagnosis.	Leukotrienes	163-174	complement C5a receptor 1	Homo sapiens	215-218	
7492759-7	1995	However, C5a induces a rapid, transient burst of leukotriene formation only if added after IL-3.	Leukotrienes	49-60	complement C5a receptor 1	Homo sapiens	9-12	
7986196-1	1994	Dibutyryl cAMP-differentiated HL-60 human leukemia cells possess receptors for the chemoattractants N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), C5a and leukotriene B4 (LTB4).	Leukotrienes	162-173	complement C5a receptor 1	Homo sapiens	154-157	
8019492-1	1994	Human neutrophils suspended in Hanks" balanced salt solution (37 degrees C, 20 mM Hepes, pH 7.2) produced extensions, elongated and developed a polarised morphology with both a pseudopod and uropod when exposed to C5a (10 nM), leukotriene B4 (10 nM), platelet activating factor (40 nM) or interleukin-8 (12.5 nM).	Leukotrienes	227-238	complement C5a receptor 1	Homo sapiens	214-217	
8245471-2	1993	IL-3 can cause a qualitative change in the mediator release pattern for C5a-mediated stimulation; without IL-3, C5a causes no leukotriene release whereas in the presence of IL-3, significant leukotriene occurs.	Leukotrienes	191-202	complement C5a receptor 1	Homo sapiens	72-75	
2474054-5	1989	Most importantly, IL-3 "primes" basophils to release large amounts of leukotriene C4 after challenge with C5a (mean of 50 gp LTC4 per nanograms cellular histamine), while neither peptide alone is capable of inducing the formation of bioactive lipids.	Leukotrienes	70-81	complement C5a receptor 1	Homo sapiens	106-109	
2045129-0	1991	Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis.	Leukotrienes	66-78	complement C5a receptor 1	Homo sapiens	39-42	
1898612-5	1991	Enhancement of leukotriene release induced by C5a by agents such as staurosporine and interleukin-3 also produced a [Ca++]i kinetic curve which resembled fmet peptide.	Leukotrienes	15-26	complement C5a receptor 1	Homo sapiens	46-49	
1898612-1	1991	Previous studies of human basophil mediator release have noted that the bacterial peptide fmet-leu-phe and the anaphylatoxin C5a induce comparable levels of histamine release while only fmet peptide induces leukotriene release.	Leukotrienes	207-218	complement C5a receptor 1	Homo sapiens	125-128	
2474054-7	1989	IL-3 affects the extent but not the time course of basophil degranulation, and leukotriene release of cells sequentially exposed to IL-3 and C5a occurs very rapidly concomitant with degranulation.	Leukotrienes	79-90	complement C5a receptor 1	Homo sapiens	141-144	
2833556-0	1988	Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5A and FMLP as second signals.	Leukotrienes	0-11	complement C5a receptor 1	Homo sapiens	166-169	
3997862-5	1985	The band is eliminated if the cross-linking experiment is performed in the presence of a large excess of unlabeled C5a, but is unaffected by the presence of nonspecific protein or the chemotactic factors N-formyl-Met-Leu-Phe and leukotriene B4.	Leukotrienes	229-240	complement C5a receptor 1	Homo sapiens	115-118	
6335143-11	1984	It was concluded that C3a acts primarily via prostaglandins and leukotrienes while C5a affects contractile intensity via vasoamines and leukotrienes.	Leukotrienes	136-148	complement C5a receptor 1	Homo sapiens	83-86	
6088878-9	1984	A competitive inhibitor of leukotriene slow-reacting substance of anaphylaxis, FPL 55712, blocked in a dose-response fashion LTB4-, C5a des arg-, and FMLP-triggered LAI.	Leukotrienes	27-38	complement C5a receptor 1	Homo sapiens	132-135